- Home
- KF vs STRO Comparison
KF vs STRO Comparison
Compare KF & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KF
- STRO
- Stock Information
- Founded
- KF 1984
- STRO 2003
- Country
- KF United States
- STRO United States
- Employees
- KF N/A
- STRO N/A
- Industry
- KF Investment Managers
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KF Finance
- STRO Health Care
- Exchange
- KF Nasdaq
- STRO Nasdaq
- Market Cap
- KF 90.9M
- STRO 77.7M
- IPO Year
- KF N/A
- STRO 2018
- Fundamental
- Price
- KF $26.99
- STRO $0.76
- Analyst Decision
- KF
- STRO Hold
- Analyst Count
- KF 0
- STRO 7
- Target Price
- KF N/A
- STRO $3.97
- AVG Volume (30 Days)
- KF 18.4K
- STRO 1.4M
- Earning Date
- KF 01-01-0001
- STRO 08-12-2025
- Dividend Yield
- KF N/A
- STRO N/A
- EPS Growth
- KF N/A
- STRO N/A
- EPS
- KF N/A
- STRO N/A
- Revenue
- KF N/A
- STRO $66,434,000.00
- Revenue This Year
- KF N/A
- STRO N/A
- Revenue Next Year
- KF N/A
- STRO N/A
- P/E Ratio
- KF N/A
- STRO N/A
- Revenue Growth
- KF N/A
- STRO N/A
- 52 Week Low
- KF $18.30
- STRO $0.52
- 52 Week High
- KF $25.56
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- KF 74.84
- STRO 44.98
- Support Level
- KF $26.48
- STRO $0.67
- Resistance Level
- KF $27.03
- STRO $0.87
- Average True Range (ATR)
- KF 0.32
- STRO 0.08
- MACD
- KF 0.00
- STRO -0.01
- Stochastic Oscillator
- KF 98.25
- STRO 34.81
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.